An interventional study of Integrated pharmacy-based AF screening circuit in Atrial Fibrillation (Prevention of Stroke), Arrythmia, Cardiac and Mass Screening, sponsored by Centro de Emergencias Sanitarias 061 Andalucía. Not yet recruiting at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Centro de Emergencias Sanitarias 061 Andalucía · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 247 studies in Atrial Fibrillation with a site in Spain — 53 open to participants now, 76 under way, 3 of them phase 3. Atrial Fibrillation · Spain.
Among the 247 studies in Atrial Fibrillation with a site in Spain, this one is the 74th largest by planned enrollment of the 162 interventional ones that give a count, is one of 10 that started in 2026, is one of 88 with no phase, reaches primary completion later than 32 of the 75 other live ones, and was the 244th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →53 of the 247 studies in Atrial Fibrillation with a site in Spain are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain, Belgium, Germany and 3 more countries
Ages 18+
Hospital Universitario Getafe · Sites in Spain
Ages 18–80
Boston Scientific Corporation · Sites in Spain, United States, Belgium and 1 more country
Ages 18+
Boston Scientific Corporation · Sites in Spain, Belgium, Croatia and 2 more countries
Ages 18+
Abbott Medical Devices · Sites in Spain, Belgium, Czechia and 7 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
247 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 37 · Phase 4 27
First in 2001; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 380 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 304 across the 162 interventional studies, 500 across the 85 observational. Of the 154 that completed or were terminated, 60 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
119 of 247 have an industry lead sponsor. The 10 most frequent:
Centro de Emergencias Sanitarias 061 Andalucía is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Centro de Emergencias Sanitarias 061 Andalucía has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
24 of the studies in Atrial Fibrillation with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07598903Centro de Emergencias Sanitarias 061 AndalucíaPharmacy-based Opportunistic Atrial Fibrillation Screening Integrated With Emergency Services (NUMAPLUS-FA) | 2026-12-15 |
| NCT07339007Societat Catalana de Medicina Familiar i Comunitària, Assoc. (CAMFiC)Observational Study to Validate a Family Physician Echocardiography Training Programme | 2026-12-31 |
| NCT07358611Hospital Clinic of BarcelonaNon-invasive Mapping-Guided Atrial Fibrillation Ablation | 2026-12-31 |
| NCT07390175Hospital San Carlos, MadridAblation of Human Cardiac Fibrillation Based on Models of Hierarchical Organization of Tissue Excitation | 2026-12-31 |
Add all 24 to your calendar (.ics) → With an account.
Among the 247 studies in Atrial Fibrillation with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the feasibility and fidelity of an opportunistic atrial fibrillation (AF) screening programme conducted in 38 community pharmacies in Seville (Spain), using the Kardias® 6-lead portable ECG device, coordinated with the emergency medical services centre Salud Responde (CES 061) and primary care physicians. Eligible participants are individuals aged 65 years or older without a prior AF diagnosis who attend a participating pharmacy for any routine purpose. The screening consists of a 30-second ECG recording performed by a trained community pharmacist. Positive or indeterminate results are transmitted in real time to Salud Responde for clinical validation and referral to primary care. The study is evaluated using the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, Maintenance). The primary outcome is protocol fidelity, measured by the Implementation Adherence Grade (IAG). The study is part of the NUMAPLUS project, funded by INTERREG VI-A España-Portugal (POCTEP 2021-2027), co-financed by the European Regional Development Fund (ERDF).
STUDY DESIGN This is a prospective, single-cohort, type-1 effectiveness-implementation hybrid study conducted within the NUMAPLUS project (INTERREG VI-A España-Portugal, POCTEP 2021-2027, co-financed by the European Regional Development Fund). This design was selected because external evidence on the diagnostic accuracy of the Kardias® device is sufficient to justify its deployment, while uncertainty persists regarding the organisational conditions, care pathways and economic incentives required for its sustainable integration into the Andalusian community pharmacy network. The primary focus is on implementation outcomes; clinical outcomes related to atrial fibrillation screening are collected as secondary endpoints. The study is reported in accordance with the Standards for Reporting Implementation Studies (StaRI) guideline.
SETTING The study is conducted in 38 community pharmacies in the province of Seville affiliated with the Real e Ilustre Colegio Oficial de Farmacéuticos de Sevilla (RICOFS), selected by voluntary participation following an open invitation. Eligibility criteria for pharmacies required stable internet connectivity for access to the Numaplus application, completion of pre-study training, and absence of concurrent participation in another cardiovascular screening programme. Priority was given to pharmacies with 24-hour or 12-hour opening schedules. Geographic coverage targets at least three urban health zones per province and at least one semi-urban or rural zone per healthcare management area.
The study articulates three coordination levels: (1) the community pharmacy as the point of patient recruitment and screening; (2) Salud Responde (CES 061) as the clinical validation, risk stratification and real-time coordination node; and (3) the primary care physician as the responsible party for definitive diagnosis and initiation of treatment.
TRAINING OF PARTICIPATING PHARMACISTS Prior to the recruitment period, all enrolled pharmacists completed a structured training programme accredited by the Escuela Andaluza de Salud Pública (EASP) and the Agencia de Calidad Sanitaria de Andalucía (ACSA). The programme was delivered entirely online in asynchronous modality between 23 March and 13 April 2026 (10 hours total) through the EASP Moodle platform. It comprised four learning units: (1) epidemiological basis and scientific rationale for opportunistic AF screening; (2) detection protocol, radial pulse palpation technique, and interpretation of Kardias® device outputs; (3) data entry in the Numaplus platform, risk classification and patient communication within the pharmacy-Salud Responde circuit; and (4) ethical and legal framework, informed consent procedures, and data protection requirements. Certification required completion of all practical activities and a minimum score of 7 out of 10 on the final knowledge assessment.
INTERVENTION
The screening protocol comprises five sequential operational phases aligned with the RE-AIM framework:
Phase 1 (Reach): Opportunistic invitation during dispensing or consultation, without prior appointment. The pharmacist records the monthly denominator of unique patients aged 65 years or older using pharmacy management software. Reasons for refusal are recorded anonymously.
Phase 2 (Adoption): Following written informed consent, the case is opened in the Numaplus application. The pharmacist records current symptoms (palpitations, chest pain, dyspnoea, syncope), oral anticoagulant therapy status, and the CHA₂DS₂-VA score (0-6), adopted per the 2024 ESC Guidelines for AF Management in replacement of CHA₂DS₂-VASc.
Phase 3 (Implementation): The Kardias® 6-lead portable device is applied for a 30-second ECG recording (maximum 3 attempts). The device algorithm classifies the result as: Suspected AF / Sinus rhythm / Bradycardia / Tachycardia / Unclassified. Protocol fidelity is operationalised through the Implementation Adherence Grade (IAG). A performance-based financial incentive of 20 euros per complete and valid case is applied.
Phase 4 (Effectiveness): In case of suspected or indeterminate AF, the Numaplus platform automatically transmits a PDF containing the ECG tracing and clinical data to Salud Responde; simultaneously, the pharmacist places a direct call. The Salud Responde nurse applies a structured triage protocol: emergency 061 activation (heart rate >110 or \<60 bpm or alarm symptoms), medium priority referral (haemodynamically stable suspected AF, primary care appointment within 72 hours), or low priority referral (unclassified tracing, scheduled ECG at primary care). Definitive AF diagnosis is confirmed by the primary care physician.
Phase 5 (Maintenance): Six-month telephone follow-up conducted by Salud Responde, assessing anticoagulation initiation and adherence, health-related quality of life (visual analogue scale 0-10), and major adverse events (ischaemic stroke, major bleeding, death).
STATISTICAL ANALYSIS The primary analysis is precision-based, targeting 385 participants (operational target: 380, 10 per pharmacy). Categorical variables are reported as proportions with 95% confidence intervals (Clopper-Pearson); the IAG is estimated with an exact binomial 95% CI. Factors associated with low fidelity are explored by logistic regression. Missing data are handled by multiple imputation (MICE, 20 imputations) if below 15% under the MAR assumption. All analyses are conducted in R version 4.3 or higher.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 65 years or older attending participating community pharmacies in Seville without prior diagnosis of atrial fibrillation, recruited opportunistically during routine pharmacy visits.
Other: Integrated pharmacy-based AF screening circuit
A coordinated opportunistic screening model integrating community pharmacies, emergency medical services (Salud Responde, CES 061) and primary care physicians. The model comprises: opportunistic patient identification during routine pharmacy visits; 30-second ECG recording using the Kardias 6-lead portable device; real-time data transmission via the Numaplus platform; structured clinical triage by Salud Responde nursing staff; and referral to primary care for definitive diagnosis and treatment. Implementation strategies include a structured EASP-accredited online training programme, ongoing technical support, activity feedback reports and a performance-based financial incentive of 20 euros per complete valid case.
Also known as: Numaplus digital platform, Salud Responde CES 061, Kardias 6-lead portable ECG device
Implementation Adherence Grade (IAG)
Implementation Adherence Grade (IAG) Composite fidelity index expressed as the percentage of mandatory protocol items completed per screening case, calculated as (number of mandatory items completed / 5) × 100. The five mandatory items, each scored dichotomously as completed (1) or not completed (0) and weighted equally, are: (1) written informed consent obtained and documented; (2) minimum demographic data recorded; (3) complete CHA₂DS₂-VA score calculated; (4) successful 30-second ECG tracing obtained within a maximum of three attempts; and (5) documented contact with Salud Responde for all cases classified as suspected or indeterminate atrial fibrillation. The pharmacy-level and study-level IAG is the mean of individual case-level IAG values. Target value: ≥90%. Unit of Measure: Percentage of mandatory protocol items completed (single composite index).
Time frame: Through study completion, an average of 6 months
Participation rate (Reach)
Proportion of patients aged 65 years or older who accept screening divided by the monthly denominator of unique patients aged 65 years or older attending each pharmacy.
Time frame: Monthly, through study completion, an average of 6 months
Pharmacy-level adoption rate
Number of pharmacies completing at least one valid screening divided by the number of invited pharmacies.
Time frame: At end of recruitment period (month 6)
Acceptability of Intervention Measure (AIM) score
Mean score of the 4-item AIM scale (range 1-5) measuring pharmacist acceptability of the screening programme.
Time frame: At end of recruitment period (month 6)
Feasibility of Intervention Measure (FIM) score
Mean score of the 4-item FIM scale (range 1-5) measuring pharmacist-perceived feasibility of the screening programme.
Time frame: At end of recruitment period (month 6)
Suspected AF detection rate.
Proportion of screened participants with Suspected AF classification by the Kardias device algorithm.
Time frame: Through study completion, an average of 6 months
Confirmed AF diagnosis rate.
Proportion of screened participants with confirmed AF diagnosis following primary care assessment.
Time frame: Through study completion, an average of 6 months
Linkage to Care rate
Proportion of participants with suspected or indeterminate AF who attend primary care appointment within the planned timeframe.
Time frame: Up to 72 hours after positive or indeterminate screening result
Oral anticoagulation initiation rate
proportion of participants with confirmed AF initiated on oral anticoagulation.
Time frame: Up to 6 months after confirmed AF diagnosis
Major adverse events at 6 months
Incidence of ischaemic stroke, major bleeding and death among participants with confirmed AF at 6-month follow-up.
Time frame: 6 months after confirmed AF diagnosis
Refusal rate and reasons
proportion of eligible patients who decline screening, with the main reason for refusal recorded anonymously.
Time frame: Monthly, through study completion, an average of 6 months
Programme sustainability intention
Proportion of pharmacists reporting intention to continue the screening programme beyond project funding period, assessed through the sustainability block of the post-study questionnaire.
Time frame: At end of recruitment period (month 6)
Salud Responde coordination performance
Operational indicators of the Salud Responde (CES 061) triage node, including median time from ECG transmission to clinical validation, distribution of triage decisions (emergency 061 activation, medium priority referral, low priority referral), and qualitative assessment of circuit barriers by the SR coordination team at end of study.
Time frame: Through study completion, an average of 6 months
13a. Salud Responde Coordination. ECG transmission.
Median time from ECG transmission to Salud Responde clinical validation (minutes)
Time frame: Through study completion, an average of 6 months
Salud Responde coordination. Triage decission
Distribution of Salud Responde triage decisions (percentage of cases in each category: emergency 061 activation / medium priority / low priority)
Time frame: Through study completion, an average of 6 months
SR circuit barrers
Qualitative assessment of circuit barriers by Salud Responde coordination team (thematic categories)
Time frame: At end of study (month 6)
Plan to share: No — Individual participant data are pseudonymised and collected within the Andalusian Public Health System (SSPA). Data are subject to Spanish data protection legislation (Organic Law 3/2018, LOPD-GDD) and EU GDPR 2016/679 and cannot be made publicly available. Anonymised aggregate data supporting the conclusions of this study may be available upon reasonable request to the corresponding author, subject to institutional approval by the Centro de Emergencias Sanitarias 061 and the Comite Coordinador de Etica de la Investigacion Biomedica de Andalucia (CCEIBA).
Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 6 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centro de Emergencias Sanitarias 061 Andalucía